Janux Therapeutics' Board reclassified director Eric Dobmeier from Class III to Class II to balance membership across director classes, with his service deemed continuous for compensation purposes.
Key takeaways
Eric Dobmeier resigned as Class III director effective April 28, 2026.
Dobmeier was immediately reappointed as Class II director post-resignation.
Reclassification shortens his term to expire at 2026 Annual Meeting instead of 2027.
Action solely to achieve equal balance among Board's three director classes.
Service continuity preserved for equity awards and non-employee director compensation.
Dobmeier continues serving on the Compensation Committee.